Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
30.43
-2.71 (-8.18%)
At close: Feb 21, 2025, 4:00 PM
31.00
+0.57 (1.87%)
After-hours: Feb 21, 2025, 6:57 PM EST
Beam Therapeutics Revenue
Beam Therapeutics had revenue of $14.27M in the quarter ending September 30, 2024, a decrease of -17.01%. This brings the company's revenue in the last twelve months to $349.64M, up 328.73% year-over-year. In the year 2023, Beam Therapeutics had annual revenue of $377.71M with 520.01% growth.
Revenue (ttm)
$349.64M
Revenue Growth
+328.73%
P/S Ratio
7.12
Revenue / Employee
$801,933
Employees
436
Market Cap
2.42B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BEAM News
- 23 days ago - Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 4 weeks ago - Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR - GlobeNewsWire
- 5 weeks ago - Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts - GlobeNewsWire
- 2 months ago - Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 2 months ago - Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 2 months ago - Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader - GlobeNewsWire
- 3 months ago - Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference - GlobeNewsWire